Organization | Synageva Biopharma

Synageva Biopharma Report issue

For profit Phase 2 Phase 4

Founded: Athens GA United States (1996)

Status: Acquired by Alexion (2015) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial

2007

NCT00497809

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2007

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AviGenics

Active Ingredients

Drugs in Phase 4 Trials (8)

Key: Synageva Biopharma (0) Acquired (8)

abacavir (ziagen) (2 trials)

atazanavir (reyataz) (1 trial)

darunavir (prezista) (1 trial)

enfuvirtide (fuzeon) (11 trials)

fosamprenavir (lexiva) (1 trial)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (2 trials)

Drugs in Phase 2 Trials (4)

Key: Synageva Biopharma (1) Acquired (3)

amprenavir (agenerase) (1 trial)

efavirenz (sustiva) (1 trial)

sargramostim (leukine) (1 trial)

tifuvirtide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Neutropenia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial APIs: 12